NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Asia Regenerative Medicine

Asia Regenerative Medicine

Private
ShenzhenHealthcare & Life Scienceshttp://www.asiaregen.com/

Last Round

Series A

Oct 30, 2025

Company Overview

Asia Regenerative Medicine is a biotechnology company that develops stem cell and tissue engineering technologies focused on addressing kidney disease and other organ-related conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Biotech Equipment, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicinestem cell therapytissue engineeringbio-artificial organorgan regenerationkidney disease treatmentexosome therapycell therapy manufacturinginduced pluripotent stem cellsiPSCGMPgood manufacturing practicebiomanufacturing equipmentdialysis enhancementbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Asia Regenerative Medicine Comparables

Compare Asia Regenerative Medicine with similar companies based on industry and business-model similarity.

Asia Regenerative Medicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rege Nephro Co., Ltd.
82%
Trestle Biotherapeutics
77%
Help Therapeutics
71%

Asia Regenerative Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 30, 2025
VC RoundJun 1, 2023
VC RoundJan 1, 2023
Pre SeedAug 17, 2021

Asia Regenerative Medicine Investors

Notable investors and investment history

Asia Regenerative Medicine investors
InvestorRounds
Kexi CapitalVC Round
DM CapitalVC Round, Series A
Xiamen High-tech InvestmentVC Round
Beijing Zhenghe Zhengxin Investment ManagementVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2023

    Raised capital from Beijing Zhenghe Zhengxin Investment Management and Sequoia China Seed Fund.

Asia Regenerative Medicine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Asia Regenerative Medicine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Asia Regenerative Medicine's valuation, stock price, and market status.

Firmographic Details

HeadquartersShenzhen
Year Founded2018
Last FundingOct 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.